JP2020504082A - 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド - Google Patents

血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド Download PDF

Info

Publication number
JP2020504082A
JP2020504082A JP2019524345A JP2019524345A JP2020504082A JP 2020504082 A JP2020504082 A JP 2020504082A JP 2019524345 A JP2019524345 A JP 2019524345A JP 2019524345 A JP2019524345 A JP 2019524345A JP 2020504082 A JP2020504082 A JP 2020504082A
Authority
JP
Japan
Prior art keywords
fviii
recombinant polypeptide
administered
polypeptide
vwf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019524345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504082A5 (enExample
Inventor
ザビーネ・ペステル
エルマー・ラクエット
トーマス・ヴァイマー
Original Assignee
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト filed Critical ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト
Publication of JP2020504082A publication Critical patent/JP2020504082A/ja
Publication of JP2020504082A5 publication Critical patent/JP2020504082A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2019524345A 2016-11-11 2017-11-10 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド Pending JP2020504082A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16198497 2016-11-11
EP16198497.6 2016-11-11
PCT/EP2017/078840 WO2018087271A1 (en) 2016-11-11 2017-11-10 Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder

Publications (2)

Publication Number Publication Date
JP2020504082A true JP2020504082A (ja) 2020-02-06
JP2020504082A5 JP2020504082A5 (enExample) 2020-12-10

Family

ID=57389201

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019524345A Pending JP2020504082A (ja) 2016-11-11 2017-11-10 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド

Country Status (12)

Country Link
US (1) US11890327B2 (enExample)
EP (1) EP3538134B1 (enExample)
JP (1) JP2020504082A (enExample)
KR (1) KR20190073576A (enExample)
CN (1) CN110381986B (enExample)
AU (1) AU2017358865A1 (enExample)
CA (1) CA3043397A1 (enExample)
DK (1) DK3538134T3 (enExample)
ES (1) ES2908008T3 (enExample)
SG (2) SG10201912768YA (enExample)
TW (1) TW201828974A (enExample)
WO (1) WO2018087271A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
DK3793588T3 (da) 2018-05-18 2025-06-16 Bioverativ Therapeutics Inc Fremgangsmåder til behandling af hæmofili a
CN114072420B (zh) * 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
KR102647642B1 (ko) * 2021-05-04 2024-03-15 (주)케어젠 혈액 응고 활성을 갖는 펩타이드와 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015519313A (ja) * 2012-04-24 2015-07-09 ノヴォ ノルディスク アー／エス 血友病の治療に適する医薬組成物

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
JPH11501506A (ja) 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
WO1997040145A1 (en) 1996-04-24 1997-10-30 The Regents Of The University Of Michigan Inactivation resistant factor viii
ATE283034T1 (de) 1998-04-27 2004-12-15 Opperbas Holding Bv Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2002060951A2 (en) 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
EP2110385A1 (en) 2001-06-14 2009-10-21 The Scripps Research Institute Stabilized factor VIII with engineered disulfide bonds
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
DE60332011D1 (de) 2002-04-29 2010-05-20 Sanquin Bloedvoorziening Antagonisten der interaktion zwischen faktor viii und lrp ("low-density lipoprotein receptor related protein")
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
SI1596887T1 (sl) 2003-02-26 2022-05-31 Nektar Therapeutics Konjugati polimer-del faktorja VIII
EP3002012A1 (en) 2003-05-06 2016-04-06 Biogen Hemophilia Inc. Clotting factor-fc chimeric proteins to treat hemophilia
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
CA2551916C (en) 2003-12-31 2014-04-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Fc-erythropoietin fusion protein with improved pharmacokinetics
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
PT2371856T (pt) 2004-11-12 2022-08-12 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
CA2591852A1 (en) 2004-12-27 2006-07-06 Baxter International Inc. Polymer-von willebrand factor-conjugates
EP1874815A1 (en) 2005-04-14 2008-01-09 CSL Behring GmbH Modified coagulation factor viii with enhanced stability and its derivates
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2010222A1 (en) 2006-03-31 2009-01-07 Baxter International Inc. Pegylated factor viii
EP3896090B1 (en) 2006-06-14 2022-01-12 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
AU2007338298B2 (en) 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
CA2690218C (en) 2007-06-13 2017-02-28 Csl Behring Gmbh Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
AU2009262476C1 (en) 2008-06-24 2016-06-02 Csl Behring Gmbh Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
PT2499165T (pt) 2009-11-13 2016-10-28 Grifols Therapeutics Inc Preparações que contêm o fator de von willebrand (vwf), e métodos, kits e utilizações relacionadas com as mesmas
WO2013093760A2 (en) 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
DK2814502T3 (en) 2012-02-15 2017-12-18 Csl Behring Gmbh Von Willebrand Factor variants with improved Factor VIII binding affinity
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
NZ703366A (en) 2012-07-11 2018-03-23 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
ES2657291T3 (es) * 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
JP2016522219A (ja) 2013-06-12 2016-07-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物
KR20170010895A (ko) 2014-06-06 2017-02-01 옥타파마 아게 인자 ⅷ 및 폰 빌레브란트 인자 펩티드를 포함하는 조제
CN106659771B (zh) 2014-07-02 2021-09-24 康诺贝林伦瑙有限公司 修饰的von Willebrand因子
CN107810194B (zh) 2015-05-22 2021-10-08 康诺贝林伦瑙有限公司 用于制备经修饰的血管性血友病因子的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015519313A (ja) * 2012-04-24 2015-07-09 ノヴォ ノルディスク アー／エス 血友病の治療に適する医薬組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLOOD, 2014, VOL.124, NO.3, PP.313-315, JPN6021044370, ISSN: 0004792681 *

Also Published As

Publication number Publication date
CN110381986A (zh) 2019-10-25
CN110381986B (zh) 2023-08-18
CA3043397A1 (en) 2018-05-17
TW201828974A (zh) 2018-08-16
EP3538134B1 (en) 2021-12-29
SG11201903954WA (en) 2019-05-30
AU2017358865A1 (en) 2019-05-09
DK3538134T3 (da) 2022-02-07
KR20190073576A (ko) 2019-06-26
US20210268071A1 (en) 2021-09-02
WO2018087271A1 (en) 2018-05-17
US11890327B2 (en) 2024-02-06
SG10201912768YA (en) 2020-02-27
EP3538134A1 (en) 2019-09-18
ES2908008T3 (es) 2022-04-27

Similar Documents

Publication Publication Date Title
EP3297656B1 (en) Truncated von willebrand factor polypeptides for treating hemophilia
US11890327B2 (en) Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
KR20180094114A (ko) 돌연변이된 절단된 폰 빌레브란트 인자
JP6651548B2 (ja) 改変フォン・ヴィルブランド因子を製造するための方法
JP7252890B2 (ja) 血友病を処置するための切断型フォン・ヴィルブランド因子ポリペプチド
US20220348637A1 (en) Polypeptides for inducing tolerance to factor viii
HK40013462B (en) Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
HK1250625B (en) Truncated von willebrand factor polypeptides for treating hemophilia
HK40008359B (en) Truncated von willebrand factor polypeptides for treating hemophilia
HK40008359A (en) Truncated von willebrand factor polypeptides for treating hemophilia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220607